Stock Monitor: Alkermes Post Earnings Reporting
LONDON, UK / ACCESSWIRE / February 16, 2018 / Active-Investors.com has just released a free research report on Valeant Pharmaceuticals International, Inc. (NYSE: VRX). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=VRX as the Company's latest news hit the wire. On February 14, 2018, the Company announced that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) submitted by the Company's division, Ortho Dermatologics, seeking approval for JEMDEL™ (halobetasol propionate 0.01%) (IDP-122) lotion for treatment for plaque psoriasis. The PDUFA action date is set for October 05, 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Alkermes PLC (NASDAQ: ALKS), which also belongs to the Healthcare sector as the Company Valeant Pharma. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/'symbol=ALKS
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Valeant Pharma International most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/'symbol=VRX
If approved, JEMDEL™ will be the first high-potency topical steroid treatment for plaque psoriasis with dosing for as long as eight weeks. In the clinical trials, the most common adverse event observed was upper respiratory tract infection.
FDA Accepted Ortho Dermatologics' NDA for IDP-121 Acne Treatment in Lotion Form
On January 12, 2018, Ortho Dermatologics announced that the FDA has accepted the NDA for IDP-121 (tretinoin 0.05%) lotion (ALTRENO™1) with a PDUFA action date of August 27, 2018. If approved, ALTRENO™ would be the first tretinoin product in lotion form rather than a gel or cream. Acne, also known as acne vulgaris, is the most common skin disease in the United States.
FDA Approved Janssen's Tremfya for Plaque Psoriasis Treatment
In July 2017, the FDA approved Janssen Biotech's TREMFYA™ (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. TREMFYA™ is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a key role in plaque psoriasis. TREMFYA™ is administered as a 100-mg subcutaneous injection every eight-week, following two starter doses at weeks 0 and 4. In clinical studies, patients receiving TREMFYA™ experienced significant improvement in skin clearance and greater improvement in symptoms of plaque psoriasis including itch, pain, stinging, burning, and skin tightness when compared with placebo at week 16.
What is Plaque Psoriasis?
Plaque psoriasis is a chronic, relapsing, inflammatory skin disorder with a strong genetic basis. The disease is rarely life threatening, but it often is intractable to treatment. Psoriatic plaques appear as raised, red patches covered with a silvery white buildup of dead skin cells or scale, which most often appear on the scalp, knees, elbows and lower back. They are often itchy and painful, and they can crack and bleed.
About Ortho Dermatologics
Ortho Dermatologics, a Valeant Pharma company, is one of the largest prescription dermatology businesses in the world dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Ortho Dermatologics portfolio includes several leading acnes, anti-fungal, and anti-infective products.
About Valeant Pharmaceuticals International, Inc.
Founded in 1960, Valeant Pharma is a multinational specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of prescription and non-prescription pharmaceutical products throughout more than 100 countries. The Company's primary focus is in the areas of dermatology and eye health. Valeant's corporate headquarters are in Laval, Quebec, with US headquarters in Bridgewater, New Jersey.
Stock Performance Snapshot
February 15, 2018 - At Thursday's closing bell, Valeant Pharma International's stock rose 1.63%, ending the trading session at $18.67.
Volume traded for the day: 8.36 million shares.
Stock performance in the last three-month - up 30.74%; previous six-month period - up 31.94%; and past twelve-month period - up 10.74%
After yesterday's close, Valeant Pharma International's market cap was at $6.54 billion.
Price to Earnings (P/E) ratio was at 4.78.
The stock is part of the Healthcare sector, categorized under the Drug Delivery industry. This sector was up 1.1% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
